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ABSTRACT
Metabolic alterations encountered in tumors are well recognized and considered 
as a hallmark of cancer. In addition to Warburg Effect, epidemiological and 
experimental studies support the crucial role of lipid metabolism in colorectal cancer 
(CRC). The overexpression of four lipid metabolism-related genes (ABCA1, ACSL1, 
AGPAT1 and SCD genes) has been proposed as prognostic marker of stage II CRC 
(ColoLipidGene signature).
In order to explore in depth the transcriptomic and genomic scenarios of ABCA1, 
ACSL1, AGPAT1 and SCD genes, we performed a transcriptomic meta-analysis in more 
than one thousand CRC individuals. Additionally we analyzed their genomic coding 
sequence in 95 patients, to find variants that could orchestrate CRC prognosis.
We found that genetic variant rs3071, located on SCD gene, defines a 9.77% of 
stage II CRC patients with high risk of death. Moreover, individuals with upregulation 
of ABCA1 and AGPAT1 expression have an increased risk of CRC recurrence, 
independently of tumor stage. 
ABCA1 emerges as one of the main contributors to signature’s prognostic effect. 
Indeed, both high ABCA1 expression and presence of tumoral genetic variants located 
in ABCA1 coding region, seem to be associated with CRC risk of death. In addition the 
non-synonymous polymorphism rs2230808, located on ABCA1, is associated with gene 
expression. Patients carrying at least one copy of minor allele showed higher levels 
of ABCA1 expression than patients carrying homozygous major allele.
This study broaden the prognostic value of ABCA1, ACSL1, AGPAT1 and SCD 
genes, independently of CRC tumor stage, leading to future precision medicine 
approaches and “omics”-guided therapies.
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INTRODUCTION
Colorectal cancer (CRC) is a heterogeneous 
disease that relevantly contributes to cancer mortality 
and morbidity. Over the past decade, many efforts have 
been performed by the scientific community, in order to 
find CRC expression patterns that allow us an accurate 
disease stratification into different prognostic subgroups 
and/or in connection with response to therapies. Next-
generation sequencing (NGS) technologies have also 
been contributing to a better understanding of the 
CRC development. Through a fully integrated view 
of the genetic and genomic changes, NGS studies have 
provide information about CRC etiology together with 
identification of driver mutations that mediate the 
carcinogenesis processes [1–4]. 
In 2015, the intrinsic heterogeneity and molecular 
complexity of CRC led several international research 
groups to share large-scale data in order to establish a 
new CRC classification based on an unbiased approach 
[5]. Four transcriptomic consensus molecular subtypes 
(CMS) of CRC were defined: CMS1 or microsatellite 
instability (MSI) immune subtype, CMS2 or canonical, 
CMS3 or metabolic and CMS4 or mesenchymal subtype. 
Specifically, metabolic subtype tumors, CMS3, have been 
characterized as those which harbor KRAS mutations, a 
mixed MSI status, low somatic copy number alterations 
(SCNA) and low CpG island methylator phenotype 
(CIMP). Furthermore, CMS3 tumors exhibit a prominent 
metabolic activation with a clear enrichment for multiple 
metabolism signatures, in connection with the presence of 
KRAS-activating mutations that have been described as 
inducing metabolic reprogramming [5].
Metabolic alterations encountered in tumors are 
frequently described, they are well recognized and 
considered as a hallmark of cancer [6]. Cancer cells adapt 
their metabolic capacities to efficiently supply their novel 
demands of growth, proliferation and survival. In addition 
to Warburg Effect, lipid metabolism has been raised as 
crucial in tumor development, necessary to satisfied tumor 
requirements of biomass and structural components [7].
In the context of lipid metabolism, we identified 
an expression signature: ColoLipidGene (ABCA1 (ATP-
Binding Cassette Subfamily-A Member), ACSL1 (Acyl-
CoA Synthetase 1), AGPAT1 (1-Acylglycerol-3-Phosphate 
O-Acyltransferase 1) and SCD (Stearoyl-CoA-desaturase 
1) genes) that predicts prognosis in CRC patients of 
stage II [8]. Furthermore, our results generated a demand 
of improving knowledge of genes implicated in lipid 
metabolism: their function, regulation and roles in CRC 
[9]. The recent availability of large databases of patients 
with CRC, allow us to explore in depth, the transcriptomic 
and genomic landscapes of ColoLipidGenes (Genes of 
ColoLipidGene signature) in all stages of CRC. Thereby, 
we performed a transcriptomic meta-analysis on stored 
data at Gene Expression Omnibus (GEO) repository. In 
addition, since passenger mutations could also be a marker 
for tumor aggressiveness and response to passenger-
exacerbating therapies [10], we explored the genomic 
coding sequence of ColoLipidGenes in CRC patients in 
order to find sequence variants and/or passenger mutations 
that could orchestrate CRC prognosis. 
Our results broaden the prognostic value of ABCA1, 
ACSL1, AGPAT1 and SCD genes in all stages of CRC, 
leading to future precision medicine approaches and 
“omics”-guided therapies.
RESULTS
Expression of metabolism-related genes is 
associated with CRC prognosis: Results from 
meta-analysis
In order to test the prognostic value of 
ColoLipidGenes for patients with CRC tumors, we 
performed a meta-analysis based on publicly available 
transcriptomic data. We investigated whether the 
individual gene expression of ABCA1, ACSL1, AGPAT1 
and SCD, was associated with recurrence in a large 
series of CRC patients of stages from I to III, using gene 
expression datasets from GEO repository database. We 
selected six CRC datasets for which disease free survival 
(DFS) information was available (recurrence and time 
until recurrence in months), and with a minimum number 
of events (>5) (GSE17536, GSE17537, GSE31595, 
GSE41258, GSE33113, GSE39582). The meta-analysis 
comprised a total number of 1025 CRC cases (Figure 1A).
ABCA1 and AGPAT1 expression had an overall 
risk effect for recurrence in CRC patients, and the 
pooled Hazard Ratio (HR), was significantly higher than 
1 (ABCA1, HR: 1.86 (CI 95%: 1.37–2.53) p = 0.0001, 
AGPAT1, HR: 1.62 (CI 95%: 1.18–2.21) p = 0.002) 
(Figure 1B). We detected a trend in association of ACSL1 
expression with overall risk effect for DFS (HR: 1.22 (CI 
95%: 0.95–1.57) p = 0.1). Apparently, we are not able to 
detect an overall risk effect for SCD mRNA expression 
(HR: 1.17 (CI 95%: 0.8–1.71) p = 0.43169).
These data consistently validate our previous 
findings since, upregulation of ABCA1, AGPAT1 and 
ACSL1 is associated with worse outcome in CRC patients. 
Moreover, our data open up the use of these three genes as 
biomarkers of recurrence in all CRC stages.
Catalog of somatic mutations in metabolism-
related genes in colon cancer
We performed targeted re-sequencing of coding 
regions of ColoLipidGenes (Figure 2A) to determine 
type and number of metabolic-genes changes in CRC 
and to asses for their prevalence in a set of 95 stage II 
CRC patients (Table 1). Following sequential filtering 
and validating the next generation sequencing (NGS) 
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Figure 1: mRNA Expression of ColoLipidGenes and CRC prognosis. (A) Clinical characteristics of GSE datasets included in the 
meta-analysis. (B) Forest plot showing the meta-analysis of hazard ratio (HR) and 95% confidence interval (CI) estimates for disease free 
survival (DFS) of lipid metabolism-related gene expression in CRC patients from six different studies. TE, seTE: Arcsine transformation 
of proportion and its standard error for individual studies. W (random): Weight of individual studies (in random effects model).
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approach with previous genotyping results (see Materials 
& Methods and Supplementary Table 1), we identified 
a total number of novel 25 single nucleotide variants 
(SNVs) mapping to three unique genes, ABCA1, ACSL1 
and AGPAT1. We did not find any SNVs in SCD gene 
(Figure 2B). We detected 15 (15.7%) CRC patients with 
single nucleotide variants (SNVs) mapping to exon 
regions of two unique genes, ABCA1 and ACSL1. We 
did not find any patient with SNVs in coding regions 
of AGPAT1 or SCD genes (Figure 2C). The mutational 
rates that we obtained, were similar to those obtained 
in publicly available databases [3, 4, 11] (Figure 2C). 
Type and frequency of SNVs found in ABCA1 gene were 
detail in Figure 2D. We detected twelve SNVs in coding 
regions of ABCA1 gene. Among them, Asp807Asn 
variant was found in three patients. Three of twelve 
SNVs were predicted to be deleterious in nature by SIFT 
and/or Polyphen algorithms [12, 13] (Figure 2D).
Table 1: Clinical characteristics of colorectal cancer patients from ColoLipidGene study (training group)
Characteristics N (%)
Patients 95 (100)
Age at Diagnosis (years)  
Mean 65.23
Median 66
Age Range 26–86 
Under 50 7 (7.4)
50–70 62 (65.3)
Over 70 26 (27.4)
Gender  
Female 39 (41.1)
Male 56 (58.9)
Stage  
IIA (T3 N0 M0) 66 (69.5)
IIB (T4 N0 M0) 29 (30.5)
Primary Tumor Location  
Cecum and Ileocecal Valve 9 (9.5)
Acending colon and Hepatic flexure 26 (27.4)
Transverse colon 8 (8.4)
Splenic flexure and Descending colon 9 (9.5)
Sigmoid colon and rectosigmoid junction 42 (44.2)
Rectum 1 (1.1)
Grade/Differentiation  
Well 7 (7.4)
Moderately 81 (85.3)
Poor 7 (7.4)
Vascular Invasion  
No 64 (67.3)
Yes 30 (31.6)
Perineural Invasion  
No 73 (76.8)
Yes 21 (22.1)
Disease Free Survival  
Patients with recurrence 20 (21.1)
Overall survival  
Nº Exitus 11 (11.6)
Oncotarget5923www.impactjournals.com/oncotarget
Associations of single nucleotide polymorphisms 
(SNPs) found in metabolism-related genes with 
colon cancer prognosis
Additionally, NGS approach allowed us to obtain 
information related to genetic polymorphisms of ABCA1, 
ACSL1, AGPAT1 and SCD genes. We found a total of 63 
SNPs (Figure 3A), 12 of them were relatively frequent 
with minor allele frequency (MAF) major than 10% and 
51 of them were infrequent with MAF minor than 10%. 
We did not found any SNPs in AGPAT1 gene. Then, 
we tested associations for metabolism-related SNPs 
with stage II CRC prognosis. We examined the impact 
on overall survival (OS) of 12 SNPs with MAF > 10% 
(Figure 3B). We found that two genetic variants were 
associated with clinical outcome of the patients, both in 
SCD gene (rs223490 and rs3071). Thus, C/- genotype 
for rs2234970 in the dominant model of inheritance 
(HR 0.11; 95% CI 0.02–0.45; p-value = 0.009) and 
C/C genotype for rs3071 in the recessive model (HR 
12.3; 95% CI 2.78–54.38; p = 0.05) were significantly 
associated with the clinical outcome of CRC patients. 
The Kaplan–Meier survival curves and the log-rank test 
also showed the association between OS and rs2234970 
(p = 0.01) and rs3071 (p = 0.003). In order to confirm 
the association of these two SNPs in SCD gene with the 
clinical outcome of CRC patients, we genotyped them in 
an independent validation set of 130 stage II CRC patients 
(validation group). Clinical characteristics of validation 
group are summarized in Supplementary Table 2. 
SNPs analysis in the validation group confirmed the 
potential prognostic value of rs3071 (HR 6.3; 95% CI 
2.13–18.61; p = 0.003) (Figure 3C). We were not able to 
replicate in the validation group, the effect of rs2234970 
on CRC prognosis (data not shown). The Kaplan–Meier 
survival curve and the log-rank test also confirmed 
the association between OS and rs3071 (p = 0.01) 
(Figure 3C). Thus, SCD genetic variant rs3071 defines 
a 9.77% of C/C CRC stage II patients with high risk 
of death. All p-values shown are adjusted for potential 
confounding factors and corrected for multiple 
comparisons by Bonferroni test.  
Figure 2: Variants of ColoLipid Genes found in colorectal cancer (CRC) patients. (A) Graphic representation of sequenced metabolism-
related genes belonging to ColoLipidGene study. (B) Oncoprint-type representation of gene variants found in this study. (C) Percentages 
of CRC patients with exonic variants found in ColoLipidGene study and in public-available databases. (D) Bi-dimensional representation 
of ABCA1 gene and corresponding exonic variants found in 95 CRC patients from ColoLipidGene study. All represented variants have not 
been previously described.
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The SNP rs3071 is located in proximal intron region 
of SCD gene next to a predicted splice region (Figure 3D). 
SCD is composed by 6 exons (Figure 2A). Only one 
transcript variant for SCD gene have been described 
(ENST00000370355). We assessed whether rs3071 
polymorphism was associated with SCD gene expression 
in the complete series of patients (training and validation 
groups). We observed that patients carrying homozygote 
C/C alleles show a trend to have higher levels of SCD 
mRNA expression than the others. However, as expected, 
due to low frequency of minor homozygote C/C, results 
showed no statistically significant correlation between 
rs3071 genotype and SCD gene expression (Figure 3E). 
Genetic variation and gene expression of ABCA1 
modulate the outcome of CRC patients
Notably, ABCA1 gene displayed the highest variation 
rate per sequenced base among ColoLipidGenes (SNVs/
base in ABCA1 = 0.003, ACSL1 = 0.002, AGPAT1 = 0.001 
and SCD = 0). Type and frequency of SNVs found in 
ABCA1 coding region were illustrated in Figure 2D. We 
studied the relationship between the presence of ABCA1 
variants and the CRC outcome. Probably due to low 
sample size and low number of genetic changes, we were 
not able to detect any statistically significant association 
(data not shown). Additionally, ABCA1 sequence data 
from 79 patients of TCGA (The Cancer Genome Atlas) 
study, were interrogated for associations with CRC 
prognosis. We observed that, CRC patients carrying at 
least, one mutation in exonic sequence of ABCA1 gene 
displayed poor overall survival (p = 0.01) (Figure 4A). 
In order to increase sample size, we pooled data from 
ColoLipidGene study (N = 95) together with TCGA study 
(N = 79) and we analyzed associations of SNVs in ABCA1 
coding region with outcome in 174 CRC patients. We 
observed a trend (p =  0.08) in the association of tumoral 
genetic variants located in ABCA1 coding region with 
CRC overall survival (Figure 4A).
Next, we assessed for associations of SNVs in 
coding region of ABCA1 with clinical and/or tumoral 
characteristics. We used data from ColoLipidGene study 
and two publicly available datasets (TCGA and DFCI 
(Dana-Farber Cancer Institute)) with the purpose of 
obtaining the maximum sample size. We detected that the 
presence of exonic variants of ABCA1 were marginally 
associated to young patients (p = 0.06) in the pooled 
dataset (N = 362) (Figure 4B). Moreover, we observed 
several associations with prognostic clinical characteristics 
such differentiation grade and tumors with vascular and 
perineural invasion (p > 0.05) (Figure 4C).
Likewise, we also analyzed in ColoLipidGene 
study, the effect of SNPs in ABCA1 gene on CRC 
development. We found that non-synonymous SNP, 
rs2230808 (Lys1587Arg), was associated with ABCA1 
gene expression (p = 0.006). Patients carrying at least one 
copy of minor allele T showed higher levels of ABCA1 
expression than patients carrying homozygous major allele 
(C/C) (Figure 4D). Moreover, we assessed the effect of 
rs2230808 together with the presence of SNVs on ABCA1 
expression levels. We observed that individuals carrying 
at least one copy of T allele in rs2230808 together with 
SNVs in coding region of ABCA1 showed higher ABCA1 
mRNA expression than those carrying any of the two 
genetic changes separately (Figure 4D).
Finally, we tested by meta-analysis, whether the 
individual gene expression of ABCA1 was associated 
with death in 1073 CRC patients of stages from I to IV, 
using six gene expression datasets from GEO repository 
database (GSE12945, GSE16125, GSE17536, GSE17537, 
GSE39582, GSE41258) (Figure 1A), for which OS 
information was available. ABCA1 expression had an 
overall risk effect for OS in CRC patients, and the pooled 
HR was 1.29 ((CI 95%: 0.99–1.69) p = 0.06) (Figure 4E). 
Collectively, these results indicate that gene 
expression together with genetic variation of ABCA1 
orchestrate CRC prognosis, being ABCA1, one of the main 
contributors of ColoLipidGene signature’s prognostic 
value. 
DISCUSSION
Metabolic signatures have acquired substantial 
relevance in the management and classification of CRC 
since the consensus molecular subtype CMS3 was recently 
redefined. CMS3 tumors exhibit a prominent metabolic 
activation with a clear enrichment for multiple metabolism 
signatures [5]. In this study, a comprehensive genomic 
analysis of genes belonging to ColoLipidGene signature 
[8] was performed. The genomic coding sequence of 
ABCA1, ACSL1, AGPAT1 and SCD genes, as well as, their 
differential expression in a genome-wide expression meta-
analysis in colorectal cancer patients were explored. 
Due to recent develop of high throughput data 
techniques, nowadays, we have the possibility to use data 
publicly deposit in big repositories [14]. ColoLipidGene 
signature was defined from a limited group of lipid-related 
genes in stage II CRC patients [8]. We extended the 
prognostic value of ColoLipidGenes to large-scale micro-
array profiling studies that include all stages of CRC cases. 
Several CRC datasets were needed to be comparable for 
meta-analysis, which required a standardized annotation. 
Two common problems of publicly available genomic 
data are the scarcity of clinical annotation and inconsistent 
definitions of clinical characteristics across independent 
datasets [13]. We reviewed original papers and performed 
curation of clinical annotations. We were able to retain, 
in several studies, the clinical variables of proven 
importance: disease free survival and overall survival 
(Figure 1A). 
Our study, provides a comprehensive, highly curated 
and efficient CRC meta-analysis of ColoLipidGenes. The 
Oncotarget5925www.impactjournals.com/oncotarget
important use of this meta-analysis is the assessment of 
ColoLipidGenes as prognostic biomarkers in all stages 
of CRC. We have validated ColoLipidGene signature 
by analyzing individual gene contribution in a huge 
population of more than one thousand CRC patients 
from six different studies and representing tumors of all 
grades (Figure 1B). Among ColoLipidGenes, uniquely, 
we were not able to replicate SCD individual effect. We 
hypothesized that SCD action could be compensated 
for ABCA1 and AGPAT1 effect. Interactions among 
ColoLipidGenes have been previously described [15–18] 
by in vitro and bioinformatics approaches, that predict 
a well-established network of action (Supplementary 
Figure 1). Unequivocally, the ABCA1 and AGPAT1 
expression seem to be important contributors to the 
ColoLipidGene signature prognostic value.
We explored genomic coding sequence of 
ColoLipidGenes in order to find passenger mutations that 
could be modulating prognosis, recurrence or outcome 
[10, 19]. It have been hypothesized a unique framework 
Figure 3: Analysis of single nucleotide polymorphisms (SNPs) of ColoLipidGenes: Prognostic value of rs3071 in stage II colorectal 
cancer (CRC) patients. (A) Number and frequency classification of SNPs investigated in 95 stage II CRC patients. (B) Location, type 
and minor allele frequency (MAF) of polymorphisms, with MAF>10%, analyzed in the study. (C) Kaplan–Meier curves of SCD rs3071, 
on OS for stage II CRC patients in a recessive model of inheritance. Common/mayor Homozygote plus Heterozygote alleles (A/A + A/C); 
Variant/ minor Homozygote allele (C/C). P-value was calculated by Log-rank test. (D) Genomic context of rs3071. rs3071 is located in an 
SCD intron, next to a splice region. (E) Box plot of the association between gene expression level for SCD and genotype for rs3071. The 
box plot show how the SCD expression values are distributed for each genotype from recessive model of inheritance in all available stage 
II CRC patients (Training and Validation groups). Common/mayor Homozygote plus Heterozygote alleles (A/A + A/C); HV, Variant/ minor 
Homozygote allele (C/C). 
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for understanding cancer progression as a balance of 
driver and passenger mutations [19]. Several studies 
suggested that mildly-deleterious passengers accumulate, 
collectively slow cancer progression, reduce the fitness of 
cancer cells and enhance the effects of therapeutics. We 
identified 15 (15.7%) CRC patients with SNVs mapping 
to exonic regions of two unique genes, ABCA1 and 
ACSL1 (Figure 2B). The ABCA1 gene have the highest 
Figure 4: Associations of ABCA1 variants and colorectal cancer (CRC). (A) Kaplan–Meier plots of ABCA1 exonic variants and CRC 
overall survival (OS). Data from two populations (ColoLipidGene and TCGA studies) of Stage II CRC patients are used. P Log Rank 
values are shown. (B) Association of exonic variants in ABCA1 gene and age of CRC diagnosis in 362 Stage II patients of three populations 
(ColoLipidGene, TCGA and DFSI studies). Student’s t-test was applied to assess statistically significant differences. (C) Associations of 
exonic variants in ABCA1 gene and tumor grade, vascular invasion and perineural invasion of CRC in Stage II patients of two datasets 
(ColoLipidGene and DFSI studies). Student’s t-test or Fisher´s exact test were applied to assess statistically significant differences. (D) 
Associations of rs2230808 T allele and/or ABCA1 exonic variants with ABCA1 levels of expression. The Mann–Whitney U-test was used 
to compare differences between two groups and the Kruskal–Wallis test for comparison of three groups. (E) Forest plot showing the meta-
analysis of hazard ratio (HR) and 95% confidence interval (CI) estimates for OS of ABCA1 gene expression in CRC patients from six 
different studies.
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mutation rate that was in the same line which that reported 
in previous studies, TCGA [3], Genentech [4] and DFCI 
[11] (Figure 2C). Data from these studies were available 
in cBioPortal database [20, 21] and occasionally, they 
allowed us to increase our sample size. 
We detected several genetic changes in ABCA1 gene 
that could be modulating CRC prognosis (Figure 2D). 
These passenger mutations could be implicated in many 
not yet known aspects of carcinogenesis and tumor 
development. We found that exonic variants of ABCA1 
gene could be associated with CRC outcome as well as 
age of tumor development, tumor grade, vascular invasion 
and perineural invasion (Figure 4A–4D). We recognize 
that the sample size of this study was relatively limited 
and we simply lacked power to detect other associations.
In addition to mutation and gene expression analysis, 
we also performed single nucleotide polymorphisms 
(SNPs) susceptibility analysis from sequencing data. SNPs 
alteration is the most common genetic variation in the 
human genome [17]. SNPs in metabolic genes and their 
association with CRC prognosis have been previously 
evaluated in our population but only for recurrence 
detection [22]. Here we described novel associations with 
tumor characteristics and with death event. 
We were able to validate SNP rs2230808 effect 
on ABCA1 expression [23–25]. Moreover, we detected 
a clear association of SCD SNP rs3071 with death event 
in both training and validation groups (Figure 3C). 
Consequently, rs3071 allow us the identification of a 
9.77% of CRC patients in risk. The SNP rs3071 is located 
in proximal intron region of SCD gene next to a predicted 
splice region. Moreover, rs3071 has been associated with 
cardiometabolic risk factors since its presence modified 
IL6 expression [23]. SCD gene seems to modulate 
CRC outcome at genomic level though rs3071 and at 
transcriptional level by interactions with ColoLipidGenes, 
specially ABCA1 and AGPAT1 [15–18] (Supplementary 
Figure 1).
Probably due to lack of statistical power, we were 
not able to detect any genetic change in exonic regions 
of AGPAT1 or any genetic association with risk in ACSL1 
gene. On the contrary, the meta-analysis showed that 
the ACSL1 levels of expression and specially those of 
AGPAT1 clearly correlated with recurrence in all CRC 
patients (Figure 1B).
Finally, our results suggested that ABCA1 gene is 
the most important contributor to prognostic value of 
ColoLipidGene metabolic signature probably though 
a combination of transcriptomic and genetic effects. 
ABCA1 has emerged as the major cellular cholesterol 
efflux transporter, which has been implicated in several 
diseases like atherosclerosis, obesity and cancer [24–26]. 
The ABCA1 expression is clearly associated with 
two indicators of CRC outcome: DFS and OS, in 
patients of all tumor stages (Figure 1B and Figure 4E). 
Moreover, we detected several genetic changes of 
ABCA1 that could be also orchestrating prognosis. 
Passenger mutations in exonic regions of ABCA1 
could be implicated in many not yet known aspects of 
carcinogenesis. Likewise SNPs located in ABCA1 are 
influencing ABCA1 expression and consequently they 
could be implicated in CRC prognosis. 
ABCA1 alterations could have a role in the transition 
among tumoral stages that must be further explored. We 
could hypothesize that responsible mechanisms will 
include cholesterol transport alterations, specific tumor 
microenvironment interactions and/or the acquisition of 
tumor aggressiveness cell properties.
We have comprehensively characterized the mutational 
and transcriptional landscapes of ColoLipidGenes: ABCA1, 
ACSL1, AGPAT1 and SCD in CRC. In the bases of precision 
medicine, it is presumed that genomic and transcriptomic 
data could be used for disease prognostication to stratify 
patients with CRC with different clinical outcomes. The 
present analysis reinforce the relevance of the prognostic 
value of ColoLipidGenes. Moreover, this study highlights 
the utility of ABCA1 and AGPAT1 as prognosis biomarkers 
of recurrence in CRC, independently of tumor stage. 
MATERIALS AND METHODS
Patients’ samples 
95 stage II CRC patients undergoing surgery 
between 2000 and 2004 in La Paz University Hospital were 
enrolled in the ColoLipidGene initial study. Population, 
tumor characteristics and inclusion criteria were described 
previously [8]. We validated the results in different sets 
of patients. SNP’s effect validation was performed in 
130 stage II CRC patients (validation group) recruited 
in different time period (between 2004 and 2008) from 
La Paz University Hospital (Madrid) [8]. For these two 
groups of patients, Formalin-Fixed, Paraffin-Embedded 
(FFPE) samples were obtained with the approval of the 
human research Ethics review Committee of the hospital 
involved (HULP-PI-1452). Clinico-histopathological data 
of patients were resumed in Table 1 and Supplementary 
Table 2. We also used population’s data extracted from 
public datasets which characteristics were summarized in 
Figure 1 and Supplementary Table 3.
Genomic analysis of ColoLipidGenes
Genomic DNA from formalin fixated paraffin 
embedded (FFPE) tissue of the patients was extracted 
using standard methods (QIAamp DNA FFPE Tissue 
Kit, Qiagen, Hilden, Germany) [22]. All DNA samples 
were quantified using Quant-iT PicoGreen dsDNA 
reagent according to the manufacturer’s instructions 
(Life Technologies, Foster City, CA). One ng of each 
sample was run on the Agilent 2100 Bioanalyzer to assess 
fragmentation and sample quality.
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Library preparation & sequencing
 An enrichment system targeting the coding regions 
of genes ABCA1, ACSL1, AGPAT1 and SCD was designed 
using Design Studio platform (Illumina) for TSCA 
(TruSeq Custom Amplicon) tools. Since samples were 
of FFPE origin and DNA degradation was anticipated, 
a double design was prepared, each targeting a different 
DNA strand, to minimize false variation rates. Designs 
expanded 100% of the regions of interest; details of 
the design can be consulted in the supplementary data 
accompanying this article (Supplementary Tables 4 and 5).
DNA samples were incubated with each of these 
collections of probes according to the manufactures 
instructions. Briefly, forward oligonucleotides were bound 
to target DNAs, extended and ligated to downstream 
primers in each of the DNA strands. Afterwards, PCR 
was used to amplify the collection of amplicons of 
each sample and to barcode individual samples by 
using the extension present in the prepared forward and 
downstream oligonucleotides. Individual profiles of these 
constructions were checked using a Bioanalyzer 2100 
(Agilent) and traces were also used to estimate DNA 
concentrations of each sample. PoolA and pool B from 
each sample corresponding to both TSCA designs were 
also pooled together. Finally, samples were equimolar 
aggregated, cleaned and titrated using qPCR (Kapa) prior 
to sequencing.
Sequencing was made using two MiSeq cartridges 
(v2, 300 cycles, pair ended2x150) run under standard 
system conditions (Illumina). Following DNA sequencing, 
reads were demultiplexed according to sample barcodes 
and quality filtered so that fastq files were prepared from 
each individual sample. On average, more than 200.000 
reads were obtained for each of the designs which 
correspond to an estimated coverage higher than 1.000×. 
Sequences were mapped to human genome using the re-
sequencing pipeline of Illumina Base Space hub and the 
manifest files provided (Illumina) were used to select the 
coordinates to call variant positions. Finally, variants were 
visualized using off-line Variant Studio (Illumina) and 
used as starting point for variant filtering. 
After sequential filtering, we compared sequencing 
results of SNPs with  previous genotyping results of these 
patients [22] in order to validate sequencing approach. 
We found more than 95% of concordant results (see 
Supplementary Table 1). 
Genotyping
130 CRC samples from validation group were 
genotyped for rs2234970 and rs3071 SNPs, both located 
in SCD gene, as it has been previously described [22]. 
Expression analysis of ColoLipidGenes 
We used RNeasy Mini Kit or RNeasy FFPE 
Kit (Qiagen, Germantown, MD, USA) following 
manufacturer’s conditions to obtain total RNA from FFPE 
tumor samples previously deparafinated. Gene expression 
analysis was performed as previously described in Vargas 
et al. [8]. 
Statistical analyses
Raw microarray data was downloaded from GEO 
database. The Aroma-affymetrix R package was used 
to analyze large volumes of data in a memory-efficient 
manner. For each study, CEL files were background 
corrected and normalized locally applying the RMA 
algorithm. 
We included six CRC datasets for which disease free 
survival (DFS) information was available (recurrence and 
time until recurrence in months), performed in Affymetrix 
HG-U133A or HG-U133_Plus_2 platforms and with a 
minimum number of events (>5). R statistical software 
was used for efficient meta-analysis of ColoLipidGenes 
expression in CRC datasets [27].
SNVs were categorized as dichotomous (for 
carrying at least one variant, presence/absence) and SNPs 
were categorized by genotype (homozygote minor allele, 
heterozygote and homozygote major allele) and checked 
for additive, dominant and recessive model. Two-tailed 
Pearson and Fisher exact tests were used to compare 
distributions or allele frequencies. Bonferroni corrections 
for multiple comparisons were performed. In order to 
assess the prognostic value of genetic variants, presence 
of SNVs and genotypes of each polymorphism were 
tested for association with DFS and OS using univariate 
Cox-regression analysis, expressed as the hazard ratio 
(HR) with 95% confidence intervals (CI). To calculate 
the effect on survival with adjustment for potential 
confounding factors, proportional hazards Cox regression 
modeling was used including only variables that were 
significant (p < 0·05) in the univariate analysis. DFS was 
defined as the time from surgery until the first documented 
tumor recurrence or death. OS was defined as the time 
from surgery until death. The Kaplan–Meier method was 
used to estimate the survival probabilities, and the log-
rank test was used to test differences between subgroups. 
Survival curves were illustrated according to the Kaplan–
Meier method and the log-rank test was used to test for 
differences between the groups. 
To evaluate the association between gene expression 
level and the different genotypes from the diverse models 
of inheritance, a non-parametric Kruskal–Wallis (KW) test 
and Analysis of Variance test (ANOVA) was performed. 
Expression data of genes (calculated with the 2–ΔCt 
method) were previously analyzed and reported in Vargas 
et al. [8]. 
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All statistical calculations were carried out using the 
R statistical software version 2.15 (www.r-project.org). 
P values < 0.05 were considered significant, and all tests 
were two sided.
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